JP2022130585A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022130585A5 JP2022130585A5 JP2022104015A JP2022104015A JP2022130585A5 JP 2022130585 A5 JP2022130585 A5 JP 2022130585A5 JP 2022104015 A JP2022104015 A JP 2022104015A JP 2022104015 A JP2022104015 A JP 2022104015A JP 2022130585 A5 JP2022130585 A5 JP 2022130585A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- peptide
- therapy
- composition
- human subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024110688A JP2024156682A (ja) | 2012-05-16 | 2024-07-10 | 癌幹細胞を標的とした癌ワクチン |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261647615P | 2012-05-16 | 2012-05-16 | |
| US61/647,615 | 2012-05-16 | ||
| JP2020065482A JP2020117519A (ja) | 2012-05-16 | 2020-04-01 | 癌幹細胞を標的とした癌ワクチン |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020065482A Division JP2020117519A (ja) | 2012-05-16 | 2020-04-01 | 癌幹細胞を標的とした癌ワクチン |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024110688A Division JP2024156682A (ja) | 2012-05-16 | 2024-07-10 | 癌幹細胞を標的とした癌ワクチン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022130585A JP2022130585A (ja) | 2022-09-06 |
| JP2022130585A5 true JP2022130585A5 (enExample) | 2022-12-16 |
Family
ID=49584234
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015512776A Withdrawn JP2015518835A (ja) | 2012-05-16 | 2013-05-15 | 癌幹細胞を標的とした癌ワクチン |
| JP2018008606A Pending JP2018109004A (ja) | 2012-05-16 | 2018-01-23 | 癌幹細胞を標的とした癌ワクチン |
| JP2020065482A Pending JP2020117519A (ja) | 2012-05-16 | 2020-04-01 | 癌幹細胞を標的とした癌ワクチン |
| JP2022104015A Pending JP2022130585A (ja) | 2012-05-16 | 2022-06-28 | 癌幹細胞を標的とした癌ワクチン |
| JP2024110688A Pending JP2024156682A (ja) | 2012-05-16 | 2024-07-10 | 癌幹細胞を標的とした癌ワクチン |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015512776A Withdrawn JP2015518835A (ja) | 2012-05-16 | 2013-05-15 | 癌幹細胞を標的とした癌ワクチン |
| JP2018008606A Pending JP2018109004A (ja) | 2012-05-16 | 2018-01-23 | 癌幹細胞を標的とした癌ワクチン |
| JP2020065482A Pending JP2020117519A (ja) | 2012-05-16 | 2020-04-01 | 癌幹細胞を標的とした癌ワクチン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024110688A Pending JP2024156682A (ja) | 2012-05-16 | 2024-07-10 | 癌幹細胞を標的とした癌ワクチン |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US10485858B2 (enExample) |
| EP (4) | EP3912634B1 (enExample) |
| JP (5) | JP2015518835A (enExample) |
| CA (2) | CA3183703A1 (enExample) |
| CY (1) | CY1124512T1 (enExample) |
| DK (1) | DK3536334T3 (enExample) |
| ES (3) | ES2967342T3 (enExample) |
| HR (1) | HRP20211432T1 (enExample) |
| HU (1) | HUE056350T2 (enExample) |
| LT (1) | LT3536334T (enExample) |
| PL (1) | PL3536334T3 (enExample) |
| PT (1) | PT3536334T (enExample) |
| RS (1) | RS62406B1 (enExample) |
| SI (1) | SI3536334T1 (enExample) |
| SM (1) | SMT202100545T1 (enExample) |
| WO (1) | WO2013173411A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013173411A1 (en) | 2012-05-16 | 2013-11-21 | Stemline Therapeutics, Inc | Cancer stem cell targeted cancer vaccines |
| US11712465B2 (en) | 2016-10-07 | 2023-08-01 | Enterome S.A. | Microbiota sequence variants of tumor-related antigenic epitopes |
| IL296165B2 (en) | 2016-10-07 | 2023-10-01 | Enterome S A | Immunogenic compounds for cancer treatment |
| CN117801069A (zh) | 2016-10-07 | 2024-04-02 | 恩特罗姆公司 | 用于癌症疗法的免疫原性化合物 |
| ES2935702T3 (es) | 2018-04-11 | 2023-03-09 | Enterome S A | Péptidos antigénicos para la prevención y el tratamiento del cáncer |
| US20210106652A1 (en) * | 2018-04-11 | 2021-04-15 | Enterome S.A. | Immunogenic Compounds For Treatment Of Fibrosis, Autoimmune Diseases And Inflammation |
| WO2021155501A1 (zh) * | 2020-02-05 | 2021-08-12 | 瓦克斯恩有限公司 | 生存素与gm-csf的融合体、编码dna、重组表达载体、抗肿瘤疫苗及其应用 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| DE4121547A1 (de) | 1991-06-28 | 1993-01-14 | Daimler Benz Ag | Mehrschichtisolierfolie |
| US6419931B1 (en) | 1991-08-26 | 2002-07-16 | Epimmune Inc. | Compositions and methods for eliciting CTL immunity |
| ATE161190T1 (de) | 1991-10-07 | 1998-01-15 | Biogen Inc | Vorbeugungsmethode oder behandlung von, durch antigen-präsentierende zellen hervorgerufene, hautkrankheiten mittels inhibitoren der cd2/lfa-3 wechselwirkung |
| US6162432A (en) | 1991-10-07 | 2000-12-19 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| AU712441B2 (en) | 1994-12-14 | 1999-11-04 | Scripps Research Institute, The | In vivo activation of tumor-specific cytotoxic T cells |
| US5837231A (en) | 1996-06-27 | 1998-11-17 | Regents Of The University Of Minnesota | GM-CSF administration for the treatment and prevention of recurrence of brain tumors |
| WO2001058479A1 (en) | 2000-02-08 | 2001-08-16 | The Penn State Research Foundation | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
| CA2671940A1 (en) | 2000-02-23 | 2001-08-30 | Cv Therapeutics, Inc. | Identification of partial agonists of the a2a adenosine receptor |
| US20030044406A1 (en) | 2001-03-02 | 2003-03-06 | Christine Dingivan | Methods of preventing or treating inflammatory or autoimmune disorders by administering CD2 antagonists in combination with other prophylactic or therapeutic agents |
| NZ528076A (en) | 2001-03-02 | 2005-09-30 | Medimmune Inc | Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists with an immunomodulatory agents, anti-inflammatory agents, TNF-alpha antagonists or CD2 binding molecules |
| FR2838742B1 (fr) | 2002-04-23 | 2004-07-09 | Inst Nat Sante Rech Med | Epitopes t de l'antigene epha2 |
| WO2004087758A2 (en) | 2003-03-26 | 2004-10-14 | Neopharm, Inc. | Il 13 receptor alpha 2 antibody and methods of use |
| KR101224235B1 (ko) | 2003-04-11 | 2013-01-25 | 메디뮨 엘엘씨 | 재조합 ｉｌ９ 항체 및 그의 용도 |
| JP2004353820A (ja) | 2003-05-30 | 2004-12-16 | Toyota Motor Corp | トリポート型等速ジョイント部品およびトリポート型等速ジョイント |
| CA2533789C (en) | 2003-07-30 | 2013-09-17 | University Of Pittsburgh Of The Commnonwealth System Of Higher Education | Epha2 t-cell epitope agonists and uses therefor |
| KR20060130038A (ko) | 2003-10-15 | 2006-12-18 | 메디뮨 인코포레이티드 | 리스테리아에 의거한 ＥｐｈＡ２ 백신 |
| JP4926714B2 (ja) | 2003-11-19 | 2012-05-09 | サーバック エーピーエス | Ｂｃｌ−２ファミリ−に属するタンパク質およびそのフラグメント、ならびに癌患者におけるそれらの使用 |
| US20050153923A1 (en) | 2003-12-04 | 2005-07-14 | Kinch Michael S. | Targeted drug delivery using EphA2 or EphA4 binding moieties |
| WO2006034334A2 (en) | 2004-09-21 | 2006-03-30 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Peptide analogs capable of enhancing stimulation of a glioma-specific ctl response |
| CN101072875B (zh) | 2004-12-07 | 2011-05-18 | 东丽株式会社 | 新型癌抗原肽及其用途 |
| DK1853305T3 (en) | 2005-02-04 | 2014-12-01 | Survac Aps | Survivin-peptide vaccine |
| US20070104689A1 (en) * | 2005-09-27 | 2007-05-10 | Merck Patent Gmbh | Compositions and methods for treating tumors presenting survivin antigens |
| EP1945754B1 (en) | 2005-10-31 | 2014-07-23 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| US8343461B2 (en) | 2006-03-08 | 2013-01-01 | Wake Forest University Health Sciences | Molecular signature of cancer |
| ATE539079T1 (de) | 2006-03-23 | 2012-01-15 | Novartis Ag | Imidazochinoxalinverbindungen als immunmodulatoren |
| CA2646891A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Immunopotentiating compounds |
| EP2783700A1 (en) | 2006-09-07 | 2014-10-01 | Stemline Therapeutics, Inc. | Cancer stem cell-targeted cancer therapy |
| US20080118432A1 (en) | 2006-09-07 | 2008-05-22 | Ivan Bergstein | Monitoring cancer stem cells |
| WO2008039969A2 (en) | 2006-09-28 | 2008-04-03 | Cedars-Sinai Medical Center | Cancer vaccines and vaccination methods |
| WO2008091908A2 (en) | 2007-01-22 | 2008-07-31 | Raven Biotechnologies | Human cancer stem cells |
| CA2694011C (en) | 2007-07-19 | 2016-01-12 | Health Research, Inc. | Survivin peptides as cancer vaccines |
| ES2536465T3 (es) | 2008-10-01 | 2015-05-25 | Immatics Biotechnologies Gmbh | Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres |
| US20110223187A1 (en) | 2010-02-15 | 2011-09-15 | Vafa Shahabi | Live listeria-based vaccines for central nervous system therapy |
| GB201004551D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| WO2012027379A2 (en) | 2010-08-24 | 2012-03-01 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines |
| US8801711B2 (en) * | 2011-06-16 | 2014-08-12 | Clifford T. Solomon | Skull clamp system with pressure limiting and alarm systems |
| WO2013173411A1 (en) | 2012-05-16 | 2013-11-21 | Stemline Therapeutics, Inc | Cancer stem cell targeted cancer vaccines |
-
2013
- 2013-05-15 WO PCT/US2013/041063 patent/WO2013173411A1/en not_active Ceased
- 2013-05-15 CA CA3183703A patent/CA3183703A1/en active Pending
- 2013-05-15 ES ES21162077T patent/ES2967342T3/es active Active
- 2013-05-15 ES ES18213178T patent/ES2890529T3/es active Active
- 2013-05-15 RS RS20211149A patent/RS62406B1/sr unknown
- 2013-05-15 SM SM20210545T patent/SMT202100545T1/it unknown
- 2013-05-15 EP EP21162077.8A patent/EP3912634B1/en active Active
- 2013-05-15 DK DK18213178.9T patent/DK3536334T3/da active
- 2013-05-15 PT PT182131789T patent/PT3536334T/pt unknown
- 2013-05-15 LT LTEP18213178.9T patent/LT3536334T/lt unknown
- 2013-05-15 CA CA2911191A patent/CA2911191C/en active Active
- 2013-05-15 PL PL18213178T patent/PL3536334T3/pl unknown
- 2013-05-15 ES ES23193214T patent/ES3074402T3/es active Active
- 2013-05-15 SI SI201331930T patent/SI3536334T1/sl unknown
- 2013-05-15 EP EP18213178.9A patent/EP3536334B1/en active Active
- 2013-05-15 US US14/401,053 patent/US10485858B2/en active Active
- 2013-05-15 EP EP13790444.7A patent/EP2849772A4/en not_active Ceased
- 2013-05-15 JP JP2015512776A patent/JP2015518835A/ja not_active Withdrawn
- 2013-05-15 HU HUE18213178A patent/HUE056350T2/hu unknown
- 2013-05-15 EP EP23193214.6A patent/EP4321218B1/en active Active
-
2018
- 2018-01-23 JP JP2018008606A patent/JP2018109004A/ja active Pending
-
2019
- 2019-10-10 US US16/599,031 patent/US11672847B2/en active Active
-
2020
- 2020-04-01 JP JP2020065482A patent/JP2020117519A/ja active Pending
-
2021
- 2021-09-13 HR HRP20211432TT patent/HRP20211432T1/hr unknown
- 2021-09-21 CY CY20211100828T patent/CY1124512T1/el unknown
-
2022
- 2022-06-28 JP JP2022104015A patent/JP2022130585A/ja active Pending
-
2023
- 2023-04-28 US US18/308,774 patent/US12357678B2/en active Active
-
2024
- 2024-07-10 JP JP2024110688A patent/JP2024156682A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2197912T3 (es) | Utilizacion de anticuerpos anti-tnf en la preparacion de medicamentos para tratar enfermedades con porcentaje serico elevado de interleucina-6. | |
| JP2025003994A (ja) | 特定の薬力学的有効期間および免疫寛容の誘発のための抗原を有する免疫抑制剤の送達 | |
| AU2002219221B2 (en) | Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors | |
| HRP20211432T1 (hr) | Cjepiva protiv raka s ciljanim djelovanjem na matične stanice raka | |
| US10556929B2 (en) | Cytotoxic T lymphocyte inducing immunogens for prevention treatment and diagnosis of dengue virus infection | |
| EP3834889A1 (en) | Treating myelomas | |
| AU2009266940A1 (en) | Synergistic induction of humoral and cellular immunity by combinatorial activation of toll-like receptors | |
| KR20120004994A (ko) | 치료적 이용 방법 | |
| EP4670788A2 (en) | TREATMENT METHODS FOR PSORIASIS USING IL-17 ANTAGONISTS | |
| CN1507355A (zh) | 使用抗egfr抗体和抗激素剂的联合疗法 | |
| JP2010516290A5 (enExample) | ||
| JP2024156682A5 (enExample) | ||
| JP2024515459A5 (enExample) | ||
| JP2018109004A5 (enExample) | ||
| CN105873941A (zh) | 生存素导向的癌症疫苗治疗 | |
| JP2023014340A (ja) | ポリマーナノ粒子 | |
| WO2021214297A1 (en) | Immunization against sars-cov-related diseases | |
| JP2025509568A5 (enExample) | ||
| CN105816885A (zh) | 一种药物白蛋白纳米粒的制备及其应用方法 | |
| KR101851666B1 (ko) | 신규 ctl 에피토프 5 연결 펩타이드 | |
| AU2014337643B2 (en) | Novel four-CTL epitope-joined peptide | |
| US12427192B2 (en) | Water soluble adjuvant and composition containing same | |
| JP2024519904A5 (enExample) | ||
| JP2023536815A5 (enExample) | ||
| Xie et al. | Anti-tumor effects of a human VEGFR-2-based DNA vaccine in mouse models |